Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN016 plus D-0502 in HR-positive, HER2-negative advanced breast cancer
CTR20255271Phase 2Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JSKN016, taragarestrant in breast cancer, sponsored by Kanion Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
JSKN016taragarestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20255271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255271.